Haleon (LON:HLN) Stock Bumped Up to “Hold” by Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft upgraded shares of Haleon (LON:HLN) to a hold rating in a report issued on Friday,Digital Look reports. They currently have GBX 310 price target on the stock, down from their prior price target of GBX 320.

A number of other brokerages also recently issued reports on HLN. Berenberg Bank increased their price target on shares of Haleon from GBX 512 to GBX 514 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 400 price objective on shares of Haleon in a research report on Friday. Finally, Royal Bank Of Canada raised their target price on Haleon from GBX 370 to GBX 390 and gave the company a “sector perform” rating in a research report on Tuesday, August 11th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Haleon presently has a consensus rating of “Hold” and an average target price of GBX 385.80.

Haleon Trading Up 0.7%

Haleon stock opened at GBX 319.90 on Friday. The company has a current ratio of 0.69, a quick ratio of 0.93 and a debt-to-equity ratio of 50.38. Haleon has a 12 month low of GBX 310.50 and a 12 month high of GBX 433.60. The stock’s 50 day simple moving average is GBX 352.97 and its two-hundred day simple moving average is GBX 360.40. The firm has a market cap of £28.14 billion, a PE ratio of 17.67, a P/E/G ratio of 1.49 and a beta of 0.24.

Haleon (LON:HLN) last issued its quarterly earnings data on Thursday, July 30th. The company reported GBX 8.60 EPS for the quarter. Haleon had a net margin of 14.55% and a return on equity of 9.89%. Analysts anticipate that Haleon will post 19.50 earnings per share for the current year.

Haleon declared that its Board of Directors has initiated a share repurchase plan on Thursday, October 29th that allows the company to buy back £500 million in outstanding shares. This buyback authorization allows the company to purchase up to 1.8% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s board believes its stock is undervalued.

Haleon News Roundup

Here are the key news stories impacting Haleon this week:

• Positive Sentiment: Haleon approved a £500 million share repurchase program, equivalent to as much as 1.8% of outstanding shares. The buyback could support earnings per share and signals that management views the shares as undervalued. Haleon Q3 Revenue Rises; Trims Annual Revenue Growth Outlook; Launches £500 Mln Share Buyback
• Positive Sentiment: Jefferies reaffirmed its buy rating and set a GBX 400 price target, implying substantial upside from recent trading levels and providing some support for the stock. Jefferies reaffirms Haleon buy rating
• Neutral Sentiment: Deutsche Bank upgraded Haleon to hold but reduced its price target to GBX 310 from GBX 320. The change reflects a more balanced view rather than a strongly bullish signal. Deutsche Bank Haleon rating update
• Neutral Sentiment: Institutional positioning was mixed, with some major investors adding Haleon shares while others reduced holdings. These moves may influence sentiment but do not establish a clear near-term direction.
• Negative Sentiment: Haleon reported third-quarter organic revenue growth of 2.6%, below expectations, and cut its 2026 organic revenue growth outlook to about 2.5% from a previous 3%–5% range. Weak cough, cold and flu demand in North America, disruption to Centrum products in China, and a planned Brazil go-to-market change contributed to the downgrade. Haleon drops after Q3 sales miss and lower 2026 growth outlook

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.